NCT07659392Not yet recruiting
Physical Activity and Cardiometabolic Health in Women With or Without Polycystic Ovary Syndrome (SCOPAP)
Cardiometabolic Health in Women With Overweight or Obesity, With or Without Polycystic Ovary Syndrome: Effects of a Targeted Adapted Physical Activity Program
Source: ClinicalTrials.gov · Last updated 22 Jun 2026
Brief summary (registry, in English)
The primary objective of this study is to investigate the effects of a multidisciplinary intervention, including a targeted adapted physical activity program, on lipid oxidation during a walking exercise in women with overweight or obesity, with or without polycystic ovary syndrome. Specifically, the study aims to compare changes in lipid oxidation before and after the intervention between women with polycystic ovary syndrome and those without polycystic ovary syndrome. The secondary objectives are to assess the impact of polycystic ovary syndrome on several physiological and metabolic parameters in women with overweight or obesity. These include: (i) resting energy metabolism; (ii) resting blood pressure and heart rate; (iii) energy expenditure, energy cost, and heart rate during a walking exercise; (iv) body composition, glycemic and lipid profiles, and circulating levels of sex hormones and adipokines; (v) movement behaviors; and (vi) physical fitness. In addition, the effect of the multidisciplinary intervention, including the adapted physical activity program, will be evaluated on these same outcomes: (i) resting energy metabolism; (ii) resting blood pressure and heart rate; (iii) energy expenditure, energy cost, and heart rate during walking exercise; (iv) body composition, glycemic and lipid profiles, and concentrations of sex hormones and adipokines; (v) movement behaviors; and (vi) physical fitness, in women with overweight or obesity, with or without polycystic ovary syndrome.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 11 Jun 2026
- Start date
- Jul 2026
- Primary completion date
- Dec 2028
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Diseases
- Obesity
- NCT number
- NCT07659392
What you commit to
- Study type: Interventional
- Planned participants: 40
- From Jul 2026 to the primary completion date, Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Women currently receiving pharmacological treatment for obesity or who have received such treatment within the past two years
Other
- Pregnancy or breastfeeding, as declared by the participant
- Postmenopausal women
- Women under legal protection measures (guardianship, curatorship, or judicial protection)
- Refusal to sign the informed consent form
Who the study is looking for
- Women aged 18 to 40 years (inclusive boundaries)
- Women with a body mass index (BMI) between 25 and 40 kg/m²
- Women performing no more than 150 minutes of moderate-to-vigorous physical activity per week
- Women able to provide informed consent to participate
- Women affiliated with a social security system
- One group will consist of women with polycystic ovary syndrome, and another group will consist of women without polycystic ovary syndrome
Age in the registry: 18 years to 40 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Clermont-Ferrand Coordinator of this site? Confirm its status | Clermont-Ferrand | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.